Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia

Incremental Value of CSF Biomarkers in Clinically Diagnosed AD and Non-AD Dementia

Background: Cerebrospinal fluid (CSF) biomarkers are used to diagnose Alzheimer disease (AD), especially in atypical clinical presentations. No consensus currently exists regarding cut-off values. This study aimed, firstly, to define optimal cut-off values for CSF biomarkers, and secondly, to invest...

Full description

Bibliographic Details
Main Authors: Jean-Baptiste Oudart, Zoubir Djerada, Vignon Nonnonhou, Sarah Badr, Laurie-Anne Bertholon, Anis Dammak, Yacine Jaidi, Jean-Luc Novella, Nicolas Pallet, Philippe Gillery, Rachid Mahmoudi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Neurology
Subjects:
Alzheimer disease
CSF biomarkers
amyloid peptide
cut-off values
diagnostic algorithm
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00560/full

Internet

https://www.frontiersin.org/article/10.3389/fneur.2020.00560/full

Similar Items